No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia Leukemia (2008) 22, 669-671; doi:10.1038/sj.leu.2404938; published online 6 September 2007 CXCL12, or stromal cell-derived factor-1 (SDF-1), initially identified as a pre-B-cell growth-stimulating factor, is constitutively synthesized and released by bone marrow (BM) stromal cells. CXCL12 signals through CXCR4, a seven transmembrane, G-protein-coupled receptor, which is broadly expressed on a variety of normal cells, either belonging or not belonging to the hematopoietic system. 1 There is an extensive body of data concerning the prominent function of CXCL12 as a potent chemoattractant for various hematopoietic cells, including the CD34 þ hematopoietic progenitor cell (HPC); indeed, the CXCL12-CXCR4 axis is considered as the major player in the regulation of homing and retention of HPC in the marrow microenvironment. 1 In addition, CXCL12 interaction with CXCR4 expressed on tumor cells may favor their survival and growth in a paracrine manner, beyond promoting their metastatic spread in organs where the level of CXCL12 reaches a critical threshold. 2 Acute myeloid leukemia (AML) cells express functional CXCR4 and respond to CXCL12 in a complex way that involves not only chemotaxis and migration beneath marrow stromal cells and to the peripheral blood (PB), but also the regulation of cell cycle progression. 3 In a prospective study in AML patients, low expression of CXCR4 on the membrane of blast cells by flow cytometry associated with a longer relapse-free and overall survival, and CXCR4 expression level maintained an independent prognostic value together with unfavorable cytogenetics in a multivariate analysis. 4 The role of CXCR4 in circulation of leukemic blasts and the development of extramedullary disease has been explored also in childhood acute lymphoblastic leukemia. A significant correlation between high-membrane level of CXCR4 and the enlargement of spleen or liver was found, independently of the count of lymphoblasts in the circulation. 5 Finally, elevated level of submicron plasma membrane vesicles expressing CXCR4 has been detected in the blood and BM fluids of AML patients, providing further evidence that the CXCR4-CXCL12 axis intervenes in AML cell trafficking and tissue dissemination.
A genetic determinant potentially affecting HPC mobilization is represented by a single-nucleotide polymorphism (SNP) in CXCL12 (G801A), which has been associated with higher number of CD34 þ cells mobilized in the PB when the less common A allele was present; 7 in this study on 63 patients with malignancies who underwent HPC mobilization with hematopoietic growth factors, the A allele was present in 67% of good mobilizers as compared to 36% of the intermediate/poor mobilizers. 7 Recently, Dommange et al., 8 in a study on 86 patients with AML, reported that the 801A carrier status (both 801A/G and 801A/A) associated with higher count of circulating AML blasts and higher frequency of extramedullary disease. Therefore, this polymorphism was proposed as a poor genetic risk factor for patients with AML, since both leukocytosis and extramedullary localization are well established negative factors for the disease outcome. Prompted by this observation, we were interested in retrospectively evaluating whether genotyping for CXCL12-G801A SNP would help in refining prognostic assessment in a population of adult AML patients diagnosed and treated in our institution. The study had received approval from Ethical Committee and all patients had given informed consent to DNA storing and analysis for research purposes.
We studied 214 adult patients with AML, median age 54 (range 17-85 years) who had median follow-up of 270 days; 114 (53%) were females. They represented a consecutive, unselected population of AML patients for whom the only inclusion criteria in the study was the availability of a stored DNA sample at the time of diagnosis and of complete chart records; acute promyelocytic FAB-M3 leukemia patients were excluded. Patient characteristics are described in Table 1 . Patients with AML M4 and M5 were considered separately from the others, due the higher frequency of extramedullary disease observed in these subtypes. Based on conventional karyotyping, 9% of the patients were in the low-risk category, while 56 and 15% were in the intermediate and high-risk category, respectively; in 43 patients (20%) karyotyping could not be performed or was not informative. Patients were diagnosed as having extramedullary disease localization when they presented involvement of at least one of the following sites: spleen, liver, lymph nodes, gums, Waldeyer's ring, testis, central nervous system and skin. Diagnosis of extramedullary site involvement was made based on clinical signs of organomegaly or tissue infiltration, eventually corroborated by any kind of diagnostic scan techniques ordered at physician's judgment. This being a single center study, criteria for diagnosing extramedullary site involvement can be considered uniform.
In order to evaluate the impact of CXCL12-G810A polymorphism on complete remission (CR) achievement, diseasefree survival (DFS) and overall survival (OS), we considered 156 patients (73% of total patients included) who were deemed eligible at diagnosis for intensive treatment. These patients were treated according to two conventional induction regimens: 65 of them (42%) received Ida-FLA regimen (Fludarabine 25 mg m À2 on days 1-4; Cytarabine 2 g m À2 on days 1-4; Idarubicin 12 mg m À2 in patients younger than 65 years, and 8 mg m À2 in patients older than 65 years, on days 2-4) while 91 patients (58%) received a '3 þ 7' course (Idarubicin 12 mg m À2 on days 1-3; Cytarabine 100 mg m À2 every 12 h on days 1-7). Patients achieving CR received a course of highdose cytarabine (3 g m À2 every 12 h on days 1, 3, 5) as consolidation therapy. Patients with high-risk cytogenetics or with adverse clinical features were designed to undergo allogeneic-stem cell transplant (SCT) from matched-related or unrelated donor, while those with low-risk cytogenetics and without adverse clinical features were offered autologous SCT; all of the others were allocated to allogeneic or autologous SCT Table 1 Clinical characteristics and laboratory parameters at diagnosis in the 214 patients with AML considered in the study Letters to the Editor depending on whether an HLA-identical related sibling was available.
CXCL12-G801A polymorphism was determined with a restriction fragment-length polymorphism PCR assay. Genomic DNA was purified from PB mononuclear cells using a QIAmp blood DNA mini kit (Qiagen, GmbH, Germany, http://www.qiagen.com).
PCR amplicons, generated using 5 0 -CAGTCAACCTGGGCAA AGCC-3 0 (forward) and 5 0 -AGCTTTGTGCCTGAGAGTC-3 0 (reverse) primers, were digested with the restriction endonuclease MspI (New England Biolabs Ltd, UK, http://www.neb.com), resulting in two fragments of 202 and 100 bp for the 801G-allele, while the 801A allele remained undigested (302 bp) because it does not contain the MspI restriction site. Digested fragments were resolved in a 3% ethidium bromide-stained agarose gel.
Data were processed using the SPSS (Statsoft Inc., Tulsa, OK, USA) software. We used the Fisher's exact test (2 Â 2 table) or w 2 -test (larger contingency table) to compare categorical variables. The analysis of continuous variables was performed using the Mann-Whitney U-test. Kaplan-Meier analysis was used to estimate DFS and OS. Unconditional logistic regression models with backward stepwise was used to assess factors which were associated with OS and DFS; age, leukocyte count, cytogenetic and CXCL12-G801A polymorphism were used as covariates. All P-values were two-sided and a value o0.05 were considered to indicate statistical significance.
Observed frequency of 801A and G allele in our patient population was that expected for a Caucasian population according to Hardy-Weinberg equilibrium; total number of patients having an A allele (that is, subjects with both AA-and AG alleles) was 93, accounting for 43% of whole patient population. There was no difference in the relative frequency of patients in the three polymorphism classes concerning with their gender, age, overall survival, AML-FAB subtype, distribution according to cytogenetic risk and frequency of secondary AML (Table 1) ; similarly, patients with the two main allele genotype pattern, 801GG versus 801AG plus AA, had similar characteristics and thus they were comparable. Considering hematologic parameters at diagnosis, we found no meaningful difference in hemoglobin, leukocyte or platelet count, percentage of either PB or BM blasts depending on CXCL12-G801A polymorphism (Table 1) . On the other hand, Dommange et al. 8 , found that the 801A allele associated with higher blast cell counts in the PB, but not in the BM. In our patient series, evidence for extramedullary dissemination of AML blast cells was found in 66 patients, accounting for 31% of total. Twenty-seven patients with extramedullary disease (41% of total) had one or two A allele(s), as compared to 39 patients (59%), who were GG; the difference was not statistically significant. These results are at variance with previous study where 19 patients (59%), among the 32 patients with extramedullary dissemination, were AA or AG as compared to 13 who were GG (41%: P ¼ 0.018). 8 We next evaluated whether CXCL12-G801A polymorphism would associate with disease outcome; for this analysis, we considered only a subgroup of 156 patients who received a homogeneous treatment protocol, according to an intention-totreat analysis; of these, 88 were GG and 68 had one or both A alleles. One hundred fourteen patients (73%) obtained a CR; of these 61 were GG and 53 had A allele, corresponding to 69 and 78% of the patients in each genotype group (P ¼ 0.71). Overall DFS was 590 days and OS was 654 days. In patients with AA þ AG/allele, OS was 557(775) days as compared to 682(783) days in the GG group (P ¼ 0.11), while corresponding figures for DFS were 554(792) days and 530(778) days (P ¼ 0.54). According to a multivariate cox proportional hazard analysis, advanced age, high-risk cytogenetic category, and leukocytosis predicted for DFS and OS, while CXCL12 genotype had no significant impact (P ¼ 0.3).
In summary, our data do not stand in favor of a role for CXCL12-G801A polymorphism genotyping in the current prognostication approach to AML patients.
